Biocardia Stock In The News

Biocardia stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Biocardia earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
There is far too much social signal, news, headlines, and media speculation about Biocardia that is available to investors today. That information is available publicly through Biocardia media outlets and privately through word of mouth or via Biocardia internal channels. However, regardless of the origin, that massive amount of Biocardia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biocardia news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biocardia relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biocardia's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biocardia alpha.

Biocardia Largest EPS Surprises

Earnings surprises can significantly impact Biocardia's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-05-11
2022-03-31-0.24-0.20.0416 
2021-11-10
2021-09-30-0.21-0.160.0523 
2021-05-13
2021-03-31-0.24-0.180.0625 
2021-03-30
2020-12-31-0.3-0.150.1550 
2020-08-13
2020-06-30-0.23-0.46-0.23100 
View All Earnings Estimates

Biocardia Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Biocardia Stock. The global stock market is bearish. About 65% of major world exchanges and indexes are down. See today's market update for more information.
Investors Business Daily at Macroaxis
21st of June 2022
Should You Hold BioCardia Inc Stock Tuesday Morning - InvestorsObserver
at www.investorsobserver.com 
news
15th of June 2022
Financial Statements
at SEC 
Macroaxis News
13th of June 2022
Purchase by Peter Altman of 4500 shares of Biocardia
at MacroaxisInsider 
news
10th of June 2022
Filing
at SEC 
Macroaxis News
18th of May 2022
Payment of 20632 shares by David McClung of Biocardia subject to Rule 16b-3
at MacroaxisInsider 
news
13th of May 2022
Purchase by Peter Altman of 2698 shares of Biocardia
at Peter Altman 
news
11th of May 2022
EPS Reported
at EPS REPORTED 
Macroaxis News
2nd of May 2022
Purchase by Peter Altman of 2700 shares of Biocardia
at MacroaxisInsider 
Investors Business Daily at Macroaxis
19th of April 2022
Premarket Mover BioCardia Inc Down 6.94 percent - InvestorsObserver
at www.investorsobserver.com 
news
18th of April 2022
Acquisition by David McClung of 60000 shares of Biocardia subject to Rule 16b-3
at David McClung 
news
12th of April 2022
Financial Statements
at SEC 

Be your own money manager

Our tools can tell you how much better you can do entering a position in Biocardia without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Transaction History Now

   

Transaction History

View history of all your transactions and understand their impact on performance
All  Next Launch Module

Pair Trading with Biocardia

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biocardia position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biocardia will appreciate offsetting losses from the drop in the long position's value.

Biocardia Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Biocardia could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biocardia when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biocardia - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biocardia to buy it.
The correlation of Biocardia is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biocardia moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biocardia moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biocardia can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Biocardia Backtesting and Biocardia Hype Analysis. Note that the Biocardia information on this page should be used as a complementary analysis to other Biocardia's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Piotroski F Score module to get Piotroski F Score based on binary analysis strategy of nine different fundamentals.

Complementary Tools for Biocardia Stock analysis

When running Biocardia price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Is Biocardia's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
25.3 M
Quarterly Revenue Growth YOY
0.3
Return On Assets
-0.45
Return On Equity
-1.0
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine Biocardia value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BCDA
 Stock
  

USD 1.49  0.03  2.05%   

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Biocardia and other traded companies coverage. We help investors stay connected with Biocardia headlines for the 5th of July to make an informed investment decision based on correlating the impacts of news items on Biocardia Stock performance. Please note that trading solely based on the Biocardia hype is not for everyone as timely availability and quick action are needed to avoid losses. As of July 5, 2022, Net Income Common Stock is expected to decline to about (13 M).
  
Refresh
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Biocardia headlines in addition to utilizing other, more conventional financial analysis modules. Continue to Biocardia Backtesting and Biocardia Hype Analysis.
Biocardia's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Biocardia investors visualize upcoming and past events in order to time the market based on Biocardia noise-free hype analysis.